-
公开(公告)号:US20180133200A1
公开(公告)日:2018-05-17
申请号:US15860852
申请日:2018-01-03
Applicant: Array BioPharma, Inc.
Inventor: Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Tony P. Tang , Li Ren
IPC: A61K31/444 , A61K31/496 , A61P35/00 , A61P35/02 , A61K45/06 , A61K31/5377 , A61K31/4985 , A61K31/506 , A61K31/551
CPC classification number: C07D471/04 , A61K31/444 , A61K31/496 , A61K31/4985 , A61K31/4995 , A61K31/506 , A61K31/5377 , A61K31/551 , A61K45/06 , A61P1/12 , A61P35/00 , A61P35/02 , A61P35/04 , C07D519/00
Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
公开(公告)号:US11807651B2
公开(公告)日:2023-11-07
申请号:US17401892
申请日:2021-08-13
Applicant: Loxo Oncology, Inc. , Array BioPharma Inc.
Inventor: Charles Todd Eary , Stacey Spencer , Zack Crane , Katelyn Chando , Sylvie Asselin , Weidong Liu , Mike Welch , Adam Cook , Gabrielle R. Kolakowski , Andrew T. Metcalf , David A. Moreno , Tony P. Tang
IPC: C07D519/00 , C07D471/04
CPC classification number: C07D519/00 , C07D471/04
Abstract: In some embodiments, provided herein is a process for preparing a compound of Formula I
or a pharmaceutically acceptable salt thereof, as disclosed herein.-
公开(公告)号:US11098064B2
公开(公告)日:2021-08-24
申请号:US16902424
申请日:2020-06-16
Applicant: Loxo Oncology, Inc. , Array BioPharma Inc.
Inventor: Charles Todd Eary , Stacey Spencer , Zack Crane , Katelyn Chando , Sylvie Asselin , Weidong Liu , Mike Welch , Adam Cook , Gabrielle R. Kolakowski , Andrew T. Metcalf , David A. Moreno , Tony P. Tang
IPC: C07D519/00 , C07D471/04
Abstract: In some embodiments, provided herein is a process for preparing a compound of Formula I or a pharmaceutically acceptable salt thereof, as disclosed herein.
-
14.
公开(公告)号:US10766881B2
公开(公告)日:2020-09-08
申请号:US16276326
申请日:2019-02-14
Applicant: Array BioPharma Inc.
Inventor: Steven W. Andrews , James F. Blake , Adam Cook , Indrani W. Gunawardana , Kevin W. Hunt , Andrew T. Metcalf , David Moreno , Li Ren , Tony P. Tang
IPC: C07D403/14 , C07D413/14 , C07D401/14 , G01N33/574 , A61K31/501 , A61K45/06 , A61K31/5377 , C12Q1/6886
Abstract: Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which X, R1, R2, R3, Ring A and z have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.
-
15.
公开(公告)号:US10208024B2
公开(公告)日:2019-02-19
申请号:US15333148
申请日:2016-10-24
Applicant: Array BioPharma, Inc.
Inventor: Steven W. Andrews , James F. Blake , Adam Cook , Indrani W. Gunawardana , Kevin W. Hunt , Andrew T. Metcalf , David Moreno , Li Ren , Tony P. Tang
IPC: C07D403/14 , C07D401/14 , C07D413/14 , A61K31/501 , A61K31/5377 , C12Q1/68 , A61K45/06 , C12Q1/6886 , G01N33/574
Abstract: Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which X, R1, R2, R3, Ring A and z have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.
-
公开(公告)号:US20180133207A1
公开(公告)日:2018-05-17
申请号:US15860894
申请日:2018-01-03
Applicant: Array BioPharma, Inc.
Inventor: Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , James Collier , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Ginelle A. Ramann , Tony P. Tang , Li Ren , Shane M. Walls
IPC: A61K31/4545 , A61K45/06 , A61P35/00 , A61P35/02 , A61K31/444 , A61K31/506 , A61K31/501 , A61K31/497 , A61K31/5377
CPC classification number: A61K31/4545 , A61K31/4162 , A61K31/444 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K45/06 , A61P1/00 , A61P1/12 , A61P35/00 , A61P35/02 , C07D471/04
Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
17.
公开(公告)号:US20190300511A1
公开(公告)日:2019-10-03
申请号:US16276326
申请日:2019-02-14
Applicant: Array BioPharma Inc.
Inventor: Steven W. Andrews , James F. Blake , Adam Cook , Indrani W. Gunawardana , Kevin W. Hunt , Andrew T. Metcalf , David Moreno , Li Ren , Tony P. Tang
IPC: C07D403/14 , C07D413/14 , C07D401/14 , G01N33/574 , A61K31/501 , A61K45/06 , A61K31/5377 , C12Q1/6886
Abstract: Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which X, R1, R2, R3, Ring A and z have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.
-
公开(公告)号:US10172851B2
公开(公告)日:2019-01-08
申请号:US15860808
申请日:2018-01-03
Applicant: Array BioPharma, Inc.
Inventor: Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Tony P. Tang , Li Ren
IPC: C07D401/02 , C07D401/10 , A61K31/437 , A61K31/4353 , A61K31/496 , C07D471/04 , A61P1/12 , A61P35/04 , C07D519/00 , A61P35/02 , A61P35/00 , A61K31/444 , A61K31/4985 , A61K31/4995 , A61K31/506 , A61K31/5377 , A61K45/06 , A61K31/551
Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
公开(公告)号:US10172845B2
公开(公告)日:2019-01-08
申请号:US15861244
申请日:2018-01-03
Applicant: Array BioPharma, Inc.
Inventor: Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , James Collier , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Ginelle A. Ramann , Tony P. Tang , Li Ren , Shane M. Walls
IPC: A61K31/437 , A61K31/4353 , A61K31/4545 , A61K31/4162 , C07D471/04 , A61P1/00 , A61P35/00 , A61P35/02 , A61K31/444 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K45/06 , A61P1/12
Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
公开(公告)号:US10112942B2
公开(公告)日:2018-10-30
申请号:US15858240
申请日:2017-12-29
Applicant: Array BioPharma, Inc.
Inventor: Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Tony P. Tang , Li Ren
IPC: C07D401/02 , C07D401/10 , A61K31/437 , A61K31/4353 , C07D471/04 , A61P1/12 , A61P35/04 , C07D519/00
Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
-
-
-
-
-
-
-
-